Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000644222 | SCV000765913 | likely benign | Tuberous sclerosis 2 | 2024-11-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001017006 | SCV001178026 | benign | Hereditary cancer-predisposing syndrome | 2022-09-28 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genome- |
RCV000644222 | SCV002041121 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004533366 | SCV004113566 | uncertain significance | TSC2-related disorder | 2023-02-28 | criteria provided, single submitter | clinical testing | The TSC2 c.1015G>A variant is predicted to result in the amino acid substitution p.Val339Ile. To our knowledge, this variant has not been reported in the literature in association with TSC2-related disease. This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-2110710-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
All of Us Research Program, |
RCV004004017 | SCV004817061 | uncertain significance | Tuberous sclerosis syndrome | 2024-05-14 | criteria provided, single submitter | clinical testing | This missense variant replaces valine with isoleucine at codon 339 of the TSC2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with tuberous sclerosis complex in the literature. This variant has been identified in 5/251362 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |